A non-invasive, needle-free platform inducing both mucosal and systemic immunity. Validated in Phase II flu trials for its safety and broad-spectrum protective potential.
AD17002 is a mucosal vaccine adjuvant that represents a major advance in next-generation immunization. It has successfully completed Phase II clinical development, including a seasonal influenza trial that demonstrated efficacy and a favorable safety profile (NCT03784885). This non-invasive, needle-free approach induces comprehensive immune protection by enhancing both mucosal IgA and systemic IgG responses at key sites of pathogen entry. The platform has also shown compelling efficacy in animal models of SARS-CoV, validating its broad potential against respiratory pathogens. By neutralizing infection early while maintaining a favorable safety profile, AD17002 offers a highly differentiated and commercially attractive solution for future respiratory disease prevention.
Nasal Spray Seasonal Flu Vaccine — Phase I (NCT03293732), Phase II (NCT03784885) AD17002 adjuvanted intranasal vaccine is safe and effective in eliciting vaccine-specific IgG and IgA.
Publications:
back to overview
